HTD:NYE-John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest (USD)

ETF | Biotechnology | New York Stock Exchange

Last Closing

USD 20.36

Change

+0.01 (+0.05)%

Market Cap

USD 0.77B

Volume

0.05M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

The Funds investment objective is to provide a high level of after-tax total return from dividend income and capital appreciation. Under normal market conditions, the Fund will invest at least 80% of its assets in dividend-paying common and preferred securities that John Hancock Advisers, LLC believes at the time of acquisition are eligible to pay dividend, which for individual shareholders, qualify for U.S. federal income taxation at rates applicable to long-term capital gains, which are taxed at a maximum rate of 15%. The Fund intends to concentrate in securities issued by U.S. corporations in the related groups of industries comprising each of the utilities sector and the financial services sector.

Inception Date: 27/02/2004

Primary Benchmark: DJ Utilities Average TR USD

Primary Index: Morningstar Mod Tgt Risk TR USD

Gross Expense Ratio: 1.64%

Management Expense Ratio:

Unadjusted Closing Price

Adjusted Closing Price

Assets

N/A

Top Holdings

N/A

Top Sectors

N/A

Top Regions

N/A

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-14 )

Largest Industry Peers for Biotechnology

Symbol Name Mer Price(Change) Market Cap
BHVN Biohaven Pharmaceutical Holdin.. 0.00 %

N/A

USD 5.40B
RCUS Arcus Biosciences Inc 0.00 %

N/A

USD 1.44B
NUVB Nuvation Bio Inc 0.00 %

N/A

USD 0.74B
DNA Ginkgo Bioworks Holdings 0.00 %

N/A

USD 0.50B
ANRO Alto Neuroscience, Inc. 0.00 %

N/A

USD 0.37B
ADCT ADC Therapeutics SA 0.00 %

N/A

USD 0.28B
CYBN Cybin Inc 0.00 %

N/A

USD 0.21B
ANVS Annovis Bio Inc 0.00 %

N/A

USD 0.11B
PLX Protalix Biotherapeutics Inc 0.00 %

N/A

USD 0.09B
ARMP Armata Pharmaceuticals Inc 0.00 %

N/A

USD 0.08B

ETFs Containing HTD

CCEF Calamos ETF Trust 3.00 % 0.00 %

N/A

USD 0.02B
FCEF First Trust Income Opport.. 0.00 % 0.85 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (New York Stock Exchange)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.33% 68% D+ 66% D+
Dividend Return 3.64% 50% F 90% A-
Total Return 10.96% 69% C- 75% C
Trailing 12 Months  
Capital Gain 3.93% 55% F 38% F
Dividend Return 8.45% 33% F 87% B+
Total Return 12.38% 58% F 47% F
Trailing 5 Years  
Capital Gain -18.23% 60% D- 26% F
Dividend Return 33.45% 33% F 88% B+
Total Return 15.22% 40% F 41% F
Average Annual (5 Year Horizon)  
Capital Gain -4.35% 55% F 21% F
Dividend Return 2.97% 58% F 41% F
Total Return 7.32% 50% F 90% A-
Risk Return Profile  
Volatility (Standard Deviation) 20.47% 90% A- 55% F
Risk Adjusted Return 14.51% 71% C- 37% F
Market Capitalization 0.77B 94% A 66% D+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.